Merck’s Covid-19 vaccines head for the scrapheap
Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.
Merck KGaA’s dual immuno-oncology weapon misfires
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
2020 drug approvals rise despite Covid-19
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
The pandemic releases its grip on clinical trials
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
